Showing results (201-210 of 222) with videos related to

Sort By:
Pageof 23
Journal for Immunotherapy of Cancer|June 29, 2023
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomasAndrew L Coveler, David C Smith, Tycel Phillips, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2023
Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical OutcomesJustin Hwang, Xiaolei Shi, Andrew Elliott, et al.
BMC Cancer|June 15, 2019
A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)Roche Kapoor, Matthew P Deek, Riley McIntyre, et al.
JCO Oncology Practice|December 19, 2024
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is NowNeal Shore, Sarah M Nielsen, Edward D Esplin, et al.
The Prostate|November 15, 2023
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectivenessChanning J Paller, Pedro C Barata, Justin Lorentz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2022
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid TumorsAtish D Choudhury, Celestia S Higano, Johann S de Bono, et al.
Scientific Reports|July 2, 2025
Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumorsJ Abraham, V Domenyuk, N Perdigones, et al.
Cancer Research Communications|December 18, 2023
Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United StatesEmily M Rencsok, Natalie Slopen, Hannah D McManus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2022
Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA TrialPhuoc T Tran, Kathryn Lowe, Hua-Ling Tsai, et al.
European Urology Open Science|December 22, 2021
Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical ProstatectomyKaren A Autio, Emmanuel S Antonarakis, Tina M Mayer, et al.
Pageof 23